Project Grant K08DK139370
Award Date
1/9/25
Completion Date
11/30/29
Dollars Obligated
$172K
Similar Awards
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $272,964 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH). The award, effective August 1, 2024 through May 31, 2026, will support research to investigate the role of SMAD1/5/8 signaling in hepatocytes and hepatic stellate cells (HSCs) in liver fibrosis. The...
This $806,452 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) supports research investigating the mechanisms that combine type 2 diabetes and non-alcoholic fatty liver disease (NAFLD). The research aims to determine how hepatic insulin resistance can lead to the progression of NAFLD to the more severe non-alcoholic steatohepatitis (NASH), and how this...
The federal Project Grant award R01DK140159, funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), aims to investigate the potential of a novel adipokine in resolving non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) in animal models. The $469,235 award, with a start date of September 1, 2024, and an ultimate completion date of June 30,...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), aims to define the role of antigen-specific T cell responses in the progression of non-alcoholic steatohepatitis (NASH), a chronic liver disease. The $599,541 award, with a project period from September 2024 to August 2025, will fund research at the University of Colorado-Denver to investigate:...
This $754,400 Project Grant award was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research (CFDA 93.847) program. The funding will support research by The University of Texas Southwestern Medical Center (UT Southwestern) to identify adaptive genetic pathways and understand how mutant clones expand within chronically damaged liver tissues, with the goal of developing therapeutic approaches...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $243,590 to the University of Chicago to investigate the role of the protein BNIP3 in regulating lipid homeostasis in the liver. The goal is to define the mechanisms by which BNIP3 influences the accumulation of lipid droplets, which is a key factor in the development of non-alcoholic...
This $272,133 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) supports research to study the role of lipid droplet proteins in regulating polyunsaturated fatty acid metabolism and eicosanoid production, and their impact on the progression of non-alcoholic fatty liver disease (NAFLD). The principal investigator will conduct a "recall-by-genotype" study to deeply...
The U.S. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a Project Grant (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) to the Icahn School of Medicine at Mount Sinai totaling $707,389.00 on August 15, 2024. The grant supports a 5-year study titled "Targeting Nonalcoholic Fatty Liver Disease During the Reproductive Period to Improve Women's Health Outcomes". The study aims to: 1) Determine the association between...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $1,391,142 to Function Therapeutics Inc. to develop novel small molecule modulators called Parmodulins that can shift protease-activated receptor 1 (PAR1) signaling in liver tissue from a pro-inflammatory to an anti-inflammatory state. The goal is to create orally-active Parmodulins...
The U.S. Department of Health and Human Services' National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $361,400 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to Oncotrap Inc. The funding supports the development of a bispecific single-domain antibody targeting the chemokines CCL2 and CCL5 for the treatment of non-alcoholic steatohepatitis (NASH). The award will enable Oncotrap to generate a human version...